Your browser doesn't support javascript.
loading
Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies.
Imahashi, Nobuhiko; Terakura, Seitaro; Kondo, Eisei; Kato, Koji; Kim, Sung-Won; Shinohara, Akihito; Watanabe, Mizuki; Fukuda, Takahiro; Uchida, Naoyuki; Kobayashi, Hikaru; Ishikawa, Jun; Kataoka, Keisuke; Shiratori, Souichi; Ikeda, Takashi; Matsuoka, Ken-Ichi; Yoshida, Shuro; Kondo, Tadakazu; Kimura, Takafumi; Onizuka, Makoto; Ichinohe, Tatsuo; Atsuta, Yoshiko; Kanda, Junya.
Afiliação
  • Imahashi N; Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan. nimahashi@med.nagoya-u.ac.jp.
  • Terakura S; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Kondo E; Department of Hematology, Kawasaki Medical School, Kurashiki, Japan.
  • Kato K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
  • Kim SW; Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Shinohara A; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
  • Watanabe M; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Fukuda T; Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Uchida N; Department of Hematology, Toranomon Hospital, Tokyo, Japan.
  • Kobayashi H; Department of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
  • Ishikawa J; Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.
  • Kataoka K; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Shiratori S; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Ikeda T; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.
  • Matsuoka KI; Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan.
  • Yoshida S; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Kondo T; Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
  • Kimura T; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Onizuka M; Preparation Department, Japanese Red Cross Kinki Block Blood Center, Osaka, Japan.
  • Ichinohe T; Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan.
  • Atsuta Y; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Kanda J; Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Bone Marrow Transplant ; 57(2): 243-251, 2022 02.
Article em En | MEDLINE | ID: mdl-34815519
ABSTRACT
We retrospectively compared the outcomes of reduced-intensity conditioning (RIC) transplantation from matched related donors (MRD; n = 266), matched unrelated donors (MUD; n = 277), and umbilical cord blood (UCB; n = 513) for mature lymphoid malignancies. The 3-year overall survival rates for the MRD, MUD, and UCB groups were 54%, 59%, and 40%, respectively (P < 0.001). Multivariate analysis showed no differences in survival between the MRD group and the MUD or UCB group. However, survival was significantly affected by the conditioning regimen and graft-versus-host disease (GVHD) prophylaxis in the UCB group, but not in the MRD and MUD groups. Notably, multivariate analysis showed that the risk of overall mortality in the UCB recipients who received the optimal conditioning regimen and GVHD prophylaxis (n = 116) was lower than that in the MRD group (relative risk [RR], 0.69; P = 0.03) and tended to be lower than that in the MUD group (RR, 0.75; P = 0.09). Our results suggest that UCB transplantation performed with the optimal conditioning regimen and GVHD prophylaxis is highly effective. Moreover, UCB is readily available. Thus, UCB transplantation with the optimal conditioning regimen and GVHD prophylaxis is preferable to MUD transplantation when MRD are not available in the setting of RIC transplantation for mature lymphoid malignancies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article